We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other foreign stocks.
In August, S&P Global Market Intelligence reported that US dividends are set to grow around 5.1% by the close of 2024. In the United States, the energy sector dominated dividend contributions, with pharmaceuticals, financial services, and banks trailing behind. Looking beyond the US, we see similar growth trends in international markets. For example, S&P expects a 3.9% year-over-year recovery in dividends in Canada, resulting in $74.4 billion in dividend payouts for 2024. Interest rate cuts by the Bank of Canada will aid this rebound in dividends. Two-thirds of the overall Canadian dividend distributions are attributed to the financial and energy sectors.
By year-end 2024, European dividends are projected to grow 4.2% year-over-year to $531.5 billion, with the banking and insurance sectors leading the charge and counteracting the weakness in the European transportation, materials, and energy industries. In the Asia-Pacific region, dividend growth is also projected to be strong. Developed markets in the Asia-Pacific – Australia, Japan, Hong Kong SAR, New Zealand, South Korea, and Singapore – are expected to grow their dividends to $370.5 billion by the end of 2024, reflecting a 5.8% year-over-year increase. According to S&P Global, 2024 is the year that Japan will overtake Hong Kong SAR in terms of the highest dividend contributions in the developed Asia-Pacific market, with an expected growth rate of over 10% for the year.
Turning back to Canada, Ryan Bushell, president and portfolio manager at Newhaven Asset Management, joined BNN Bloomberg on February 4 and discussed the Canadian stock market outlook. He commented that the current hostility from the US should be a wake-up call for Canadian policymakers, noting that it is impractical to isolate the US but Canada should have alternative trading partners in case political tensions influence economic decisions. Bushell mentioned that having export options other than oil is crucial and that Canada should look into exporting natural gas and liquefied petroleum gases as well. In terms of investment strategies, the portfolio manager emphasized that sustainable and stable companies make for excellent long-term investments, regardless of who occupies the White House. This includes critical infrastructure companies, which cater to people’s needs rather than wants. He went on to recommend his top stock picks, which were companies with steady dividend policies, high yields, and 40-60% of their revenues coming from the US, to navigate the messy tariffs. Bushnell prefers Canadian energy stocks since these companies are seeking to export to more countries, which will result in higher gains.
Our Methodology
For this article, we used the Finviz stock screener to filter out dividend stocks listed on US exchanges but headquartered internationally. We focused on picking stocks with a consistent record of paying dividends, offering dividend growth, and being financially stable to steer clear of yield traps. The list below is ranked in the ascending order of Q3 2024 hedge fund sentiment, and dividend yields are mentioned as of February 3.
At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here)
A doctor holding a microscope in front of a laboratory sample of healthcare products.
Novartis AG (NYSE:NVS)
Dividend Yield as of February 3: 3.57%
Number of Hedge Fund Holders: 24
Novartis AG (NYSE:NVS) ranks 8th on our list of the best foreign stocks for passive income. It is a Swiss global healthcare company that develops, manufactures, and sells prescription medicines. The company’s therapeutic areas include heart, kidney, and metabolic health, immunology, neuroscience, cancer, eye care, and blood disorders.
Novartis announced positive results of its Phase III STEER study on December 30, 2024, which refers to the clinical efficiency and safety of OAV101 IT. OAV101 IT is a gene therapy meant for spinal muscular atrophy (SMA) type 2, in patients aged two to under eighteen. The results showed significant improvement in motor function compared to a sham control. Novartis AG (NYSE:NVS) plans to forward these results to the FDA in 2025 for approval.
On January 31, 2025, the Swiss healthcare giant reported its Q4 2024 earnings. After adjustments for special items, the net income climbed 26% to $3.93 billion, which beat Wall Street expectations of $3.64 billion. According to the Q4 earnings call, Novartis AG (NYSE:NVS)’s sales grew 16% on a constant currency basis during the quarter. Excluding the heart failure drug Entresto, which will lose its patent in mid-2025, the Novartis brand portfolio grew about 38%. This led the company to offer a 5% plus sales guidance until 2029, as well as a long-term growth forecast in the mid-single digits.
In the fourth quarter, Novartis also experienced a record-high free cash flow, which soared 24% to $16.3 billion. NVS attributes its stellar cash flow to its transformation into a pure pharmaceutical play. The company is set on sharing its success with shareholders and is on track to execute share buybacks of $5.4 billion in 2025. Novartis AG (NYSE:NVS) also declared an increase of 6% in its per-share dividend, which now stands at CHF 3.50. This marks the 28th consecutive yearly dividend hike by Novartis.
At the end of the third quarter, 24 Wall Street funds held shares of Novartis AG (NYSE:NVS), with the largest stakeholder being Jim Simons’ Renaissance Technologies, owning 2.3 million shares valued at $264.6 million.
Overall NVS ranks 8th on our list of the best foreign stocks with dividends for passive income. While we acknowledge the potential of NVS as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NVS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stock To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.